Arca
Skip to content
Tools
Tools

CHRNA7: Neuronal acetylcholine receptor subunit alpha-7

Component of neuronal acetylcholine receptors (nAChRs) that function as pentameric, ligand-gated cation channels with high calcium permeability among other activities. nAChRs are excitatory neurotrasnmitter receptors formed by a collection of nAChR subunits known to mediate synaptic transmission in the nervous system and the neuromuscular junction.

  • Drugs that act on it: 17
  • Approved: 0
  • In phases 1 to 3: 17
  • Sponsors: 12

Who is on it, and how far along

Every drug ChEMBL records acting on CHRNA7, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 13
  • Other 4

Approved0

    Phase 31

    • Encenicline

    Phase 212

    • ABT-126
    • AQW051
    • ASM-024
    • AZD0328
    • BNC-210
    • Bradanicline
    • Facinicline
    • GTS-21
    • JNJ-39393406
    • ND0801
    • SSR180711
    • TC-6987

    Phase 14

    • ABT-107
    • APN1125
    • AVL-3288
    • PHA-543613

    Sponsors

    Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

    • CoMentis212%
    • Asmacure Ltée16%
    • FORUM Pharmaceuticals Inc16%
    • Memory Pharmaceuticals16%

    The landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
    EnceniclinePhase 3FORUM Pharmaceuticals IncSmall moleculePartial agonistNeuronal acetylcholine receptor protein alpha-7 subunit partial agonist0
    ABT-126Phase 2AbbVieSmall moleculeAgonistNeuronal acetylcholine receptor protein alpha-7 subunit agonist0
    AQW051Phase 2Novartis PharmaceuticalsSmall moleculePartial agonistNeuronal acetylcholine receptor protein alpha-7 subunit partial agonist0
    ASM-024Phase 2Asmacure LtéeOtherModulatorNeuronal acetylcholine receptor protein alpha-7 subunit modulator0
    AZD0328Phase 2AstraZeneca PharmaceuticalsSmall moleculeAgonistNeuronal acetylcholine receptor protein alpha-7 subunit agonist0
    BNC-210Phase 2BionomicsOtherNegative allosteric modulatorNeuronal acetylcholine receptor protein alpha-7 subunit negative allosteric modulator0
    BradaniclinePhase 2TargaceptSmall moleculeAgonistNeuronal acetylcholine receptor protein alpha-7 subunit agonist0
    FaciniclinePhase 2Memory PharmaceuticalsSmall moleculePartial agonistNeuronal acetylcholine receptor protein alpha-7 subunit partial agonist0
    GTS-21Phase 2CoMentisSmall moleculeAgonistNeuronal acetylcholine receptor protein alpha-7 subunit agonist0
    JNJ-39393406Phase 2Johnson & JohnsonSmall moleculePositive allosteric modulatorNeuronal acetylcholine receptor protein alpha-7 subunit positive allosteric modulator0
    ND0801Phase 2Mitsubishi Tanabe PharmaOtherAgonistNeuronal acetylcholine receptor protein alpha-7 subunit agonist0
    SSR180711Phase 2SanofiSmall moleculePartial agonistNeuronal acetylcholine receptor protein alpha-7 subunit partial agonist0
    TC-6987Phase 2TargaceptSmall moleculeAgonistNeuronal acetylcholine receptor protein alpha-7 subunit agonist0
    ABT-107Phase 1—Small moleculeAgonistNeuronal acetylcholine receptor protein alpha-7 subunit agonist0
    APN1125Phase 1CoMentisOtherPartial agonistNeuronal acetylcholine receptor protein alpha-7 subunit partial agonist0
    AVL-3288Phase 1—Small moleculePositive allosteric modulatorNeuronal acetylcholine receptor protein alpha-7 subunit positive allosteric modulator0
    PHA-543613Phase 1—Small moleculeAgonistNeuronal acetylcholine receptor protein alpha-7 subunit agonist0

    Diseases most associated with it

    Open Targets association score, 0 to 1; all associations
    • Alzheimer disease0.44
    • Neurodegenerative disease0.35
    • Increased total eosinophil count0.32
    • Abnormality of limbs0.31
    • Male reproductive organ cancer0.27
    • Preeclampsia0.27
    • Kidney disorder0.25
    • Parkinson disease0.24
    • Lysosomal storage disease0.21

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2492, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-22. Gene name, function (UniProt P36544, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

    Esc

    Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

    Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.